Issues related to the pharmacological management of patients with brain tumours and epilepsy

Functional Neurology

Volumn 21, Issue 1, 2006, Pages 15-19

  Maschio, Marta ^a   Dinapoli, Loredana ^a   Zarabla, Alessia ^a   Jandolo, Bruno ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Adverse effects; AEDs; Brain tumours; Epilepsy; Interactions

Indexed keywords

9 AMINOCAMPTOTHECIN; ANTACID AGENT; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CARBAMAZEPINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETIRACETAM; FELBAMATE; GABAPENTIN; IFOSFAMIDE; LAMOTRIGINE; METHOTREXATE; NITROSOUREA; OXCARBAZEPINE; PACLITAXEL; PHENOBARBITAL; PHENYTOIN; PROCARBAZINE; TAMOXIFEN; TENIPOSIDE; THIOTEPA; TIAGABINE; TOPIRAMATE; TOPOTECAN; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; VINCRISTINE;

ADD ON THERAPY; AGRANULOCYTOSIS; ATAXIA; BEHAVIOR DISORDER; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; BRAIN DISEASE; BRAIN TUMOR; CANCER PATIENT; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; DATA ANALYSIS; DEPRESSION; DIPLOPIA; DISEASE EXACERBATION; DIZZINESS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BINDING SITE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG METABOLISM; DRUG PROTEIN BINDING; EOSINOPHILIA; EPILEPSY; HEADACHE; HUMAN; HYPONATREMIA; IMPOTENCE; INCIDENCE; LANGUAGE DISABILITY; LEUKOPENIA; MEDICAL LITERATURE; MEGALOBLASTIC ANEMIA; MEMORY DISORDER; MENTAL DETERIORATION; MENTAL DISEASE; META ANALYSIS; MOOD DISORDER; MOTOR DYSFUNCTION; NAUSEA; NEUROLOGIC DISEASE; NEUROPSYCHOLOGY; NEUROTOXICITY; OSTEOPENIA; PAIN; PATIENT CARE; PERIARTHRITIS; PSYCHOSIS; QUALITY OF LIFE; RESTLESSNESS; SEIZURE; SHORT SURVEY; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT PLANNING; VISUAL DISORDER;

ANTICONVULSANTS; BRAIN NEOPLASMS; DRUG INTERACTIONS; EPILEPSY; HUMANS;

EID: 33745586750     PISSN: 03935264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (26)

1. Glantz MJ, Cole BF, Forsyth PA et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;54:1886-1893
2. Pace A, Bove L, Innocenti P et al. Epilepsy and glioma: incidence and treatment in 119 patients. J Exp Clin Cancer Res 1998;17:479-482
3. Telfeian AE, Philips MF, Crino PB, Judy KD. Postoperative epilepsy in patients undergoing craniotomy for glioblastoma multiforme. J Exp Clin Cancer Res 2001;20:5-10
4. Schaller B, Ruegg SJ. Brain tumor and seizures: pathophysiology and its implications for treatment revisited. Epilepsia 2003;44:1223-1232
5. DeAngelis LM. Brain tumors. N Engl J Med 2001;344:114-123
6. Spina E, Perucca E. Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia 2002;43(Suppl 2):37-44
7. Klein M, Engelberts NHJ, van der Ploeg HM et al. Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann Neurol 2003;54:514-520
8. Patsalos PN, Froscher W, Pisani F, van Rijn C. The importance of drug interactions in epilepsy therapy. Epilepsia 2002;43:365-385
9. Wellington K, Goa KL. Oxcarbazepine: an update of its efficacy in the management of epilepsy. CNS Drugs 2001; 15:137-163
10. Wen PY, Marks PW. Medical management of patients with brain tumors. Curr Opin Oncol 2002;14:299-307
11. Hildebrand J. Management of epileptic seizures. Curr Opin Oncol 2004;16:314-317
12. Micali G, Linthicum K, Han N, West DP. Increased risk of erythema multiforme major with combination anticonvulsant and radiation therapies. Pharmacotherapy 1999;19: 223-227
13. Aguiar D, Pazo R, Duran I et al. Toxic epidermal necrolysis in patients receiving anticonvulsants and cranial irradiation: a risk to consider. J Neurooncol 2004;66:345-350
14. Bourg V, Lebrun C, Chichmanian RM, Thomas P, Frenay M. Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. Ann Oncol 2001;12:217-219
15. Sabers A, Møoller A, Dam M, et al. Cognitive functions and anticonvulsant therapy: effect of monotherapy in epilepsy. Acta Neurol Scand 1995;92:19-27
16. Curran HV, Java R. Memory and psychomotor effects of oxcarbazepine in healthy human volunteers. Eur J Clin Pharmacol 1993;44:529-533
17. Wellington K, Goa KL. Oxcarbazepine: an update of its efficacy in the management of epilepsy. CNS Drugs 2001; 15:137-163
18. Salinsky MC, Storzbach D, Spencer DC, Oken BS, Landry T, Dodrill CB. Effects of topiramate and gabapentin on cognitive abilities in healthy volunteers. Neurology 2005;64: 792-798
19. Meador KJ, Loring DW, Hulihan JF, Kamin M, Karim R; CAPSS-027 Study Group. Differential cognitive and behavioral effects of topiramate and valproate. Neurology 2003;60:1483-1488
20. Kilpatrick ES, Forrest G. Brodie MJ. Concentration-effect and concentration-toxicity relations with lamotrigine: a prospective study. Epilepsia 1996;37:534-538
21. Sander JW, Hart YM, Trimble MR, Shorvon SD. Vigabatrin and psychosis. J Neurol Neurosurg Psychiatry 1991;54: 435-439
22. Dichter MA, Brodie MJ. New antiepileptic drugs. N Engl J Med 1996;334:1583-1590
23. Leppik IE. Three new drugs for epilepsy: levetiracetam, oxcarbazepine and zonisamide. J Child Neurol 2002;17 (Suppl 1):S53-57
24. Sheth RD. Bone health in epilepsy. Lancet Neurol 2004;3:516
25. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003;2:347-356
26. Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2003;2:404-409